rival otsuka is working on a once a month injectable drug that could get approval as soon as tomorrowfda approval could be good for alkermes. the company reported a fabulous quarter at the end of january, raised guidance the third time in a row and after speculating up to 23, the stock is below 23. smells like an opportunity to me. let's check in with richard pops. chair and ceo of alkermes. welcome back. >> good to see you. >> i want to let viewers in the kitchen. i was very intrigued by the drug we're talking about, this ch is this drug that you are working on in phase three, the one otsuka is completing against, the antipsychotic. you wanted to make sure that this rival company could be approved tomorrow. >> tomorrow. >> but a lot of literature is about how good the drug is. if someone is coming in against you, why is that a focus? would why would you talk about it? >> two schools of thought. more competition is better. in the u.s., 2% of patients with schizophrenia end up on long acting medications, despite the fact that it's better for them to remember taking their medication eac